{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-071746","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.034493+00:00","generated_at":"2026-06-21T20:48:55.853701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Unicycive Therapeutics reports Q3 2022 net loss of $5.6M and provides pipeline updates","bullets":["Completed enrollment of pivotal bioequivalence study for RENAZORB; topline data expected by year-end.","Entered partnership with Lee's Pharmaceutical for RENAZORB in China, receiving $1.0M upfront fee.","Expects clearance for Phase 1 study of UNI-494 in UK by year-end.","Net loss for Q3 2022 was $5.6M vs $5.2M in Q3 2021; cash and equivalents totaled $7.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-071746","json":"https://secwatch.observer/filing/0001213900-22-071746.json","markdown":"https://secwatch.observer/filing/0001213900-22-071746.md","text":"https://secwatch.observer/filing/0001213900-22-071746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/0001213900-22-071746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/ea168550-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:48:55.853701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63468d5c22d327c2610493fd1026dd9be50635d9","claim":"Unicycive Therapeutics, Inc. reported financial results for three months ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Unicycive Therapeutics, Inc. issued a press release announcing company highlights and financial results for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/0001213900-22-071746-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}